RNA Editing for Neurodegeneration: Mechanisms, Clinical Implications, and Emerging Therapies

Abstract

RNA editing has emerged as a critical post-transcriptional mechanism with significant implications in neurodegenerative diseases. This review synthesizes current evidence on the role of RNA editing in the pathophysiology, clinical presentation, and management of neurodegenerative disorders. We discuss the epidemiological context, underlying molecular mechanisms, risk factors, and diagnostic advancements, with a focus on adenosine-to-inosine (A-to-I) editing. Recent technological breakthroughs and guideline recommendations are evaluated, aiming to inform clinical practice and highlight future research directions.

Introduction

Neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and Huntington's disease (HD), represent a major global health challenge due to their increasing prevalence and lack of curative treatments. RNA editing, particularly A-to-I editing mediated by adenosine deaminases acting on RNA (ADARs), has been identified as a key regulatory process influencing neuronal gene expression, protein diversity, and synaptic function. Disruptions in RNA editing have been implicated in neurodegeneration, prompting a deeper exploration into its therapeutic potential and clinical applications.

Epidemiology / Disease Burden

The global burden of neurodegenerative diseases is escalating, with an estimated 55 million people affected by dementia worldwide, projected to rise to 78 million by 2030. Parkinson's disease affects over 10 million individuals globally, and ALS and HD, though rarer, contribute significantly to morbidity and mortality. The economic and social costs are profound, emphasizing the urgent need for innovative molecular interventions such as RNA editing-based approaches.

Pathophysiology

RNA editing alters nucleotide sequences in RNA transcripts, most commonly through A-to-I conversion catalyzed by ADAR enzymes. In the central nervous system, RNA editing regulates the function of neurotransmitter receptors, ion channels, and synaptic proteins. Dysregulated editing leads to aberrant protein isoforms, disrupted neurotransmission, excitotoxicity, and impaired neuronal resilience. For example, deficient editing of the GluA2 subunit of AMPA receptors increases calcium permeability, contributing to neuronal vulnerability in ALS and AD. In PD, altered editing of serotonin and glutamate receptors impacts motor and cognitive function. These mechanistic insights reveal RNA editing as a pivotal modulator of neurodegenerative cascades.

Risk Factors

Genetic predisposition, aging, environmental exposures, and chronic inflammation modulate RNA editing efficiency and fidelity. Polymorphisms in ADAR genes and regulatory elements can diminish editing activity, predisposing individuals to neurodegenerative diseases. Age-related decline in editing correlates with disease onset and progression. Chronic neuroinflammation and oxidative stress further impair ADAR expression and function, exacerbating pathogenic processes.

Clinical Features

Neurodegenerative diseases manifest with progressive cognitive, behavioral, and motor deficits. AD typically presents with memory loss, executive dysfunction, and neuropsychiatric symptoms. PD is characterized by bradykinesia, rigidity, tremor, and non-motor features such as mood disturbances. ALS leads to progressive muscle weakness, spasticity, and respiratory compromise. HD combines movement abnormalities with psychiatric and cognitive decline. Emerging data suggest that altered RNA editing patterns may correlate with disease severity, clinical heterogeneity, and rate of progression, providing potential biomarkers for early detection and stratification.

Diagnosis

Diagnosis of neurodegenerative diseases relies on clinical assessment, neuroimaging, and molecular biomarkers. Advances in high-throughput sequencing and transcriptomics have enabled the identification of disease-specific RNA editing signatures in cerebrospinal fluid, blood, and brain tissue. Quantification of editing events in genes such as GRIA2, HTR2C, and SNCA may facilitate early diagnosis and monitoring of disease progression. Integrating RNA editing analysis into diagnostic algorithms holds promise for enhancing precision medicine in neurology.

Treatment & Management

Current management strategies for neurodegenerative diseases are predominantly symptomatic, with limited disease-modifying options. Pharmacological therapies target neurotransmitter systems, neuroinflammation, and protein aggregation. Emerging approaches aim to restore RNA editing balance, either by enhancing endogenous ADAR activity or through engineered RNA editors. RNA editing-based therapies offer the potential to correct pathogenic mutations, normalize aberrant splicing, and restore protein function, thereby addressing underlying disease mechanisms.

Recent Advances / Emerging Therapies

Recent advances in RNA editing technology, including programmable RNA editors such as CRISPR-Cas13 and engineered ADARs, have demonstrated precise and efficient transcriptome modification in preclinical models of neurodegeneration. Proof-of-concept studies in ALS and HD mouse models report functional recovery and delayed disease progression following targeted RNA editing interventions. Clinical trials evaluating the safety and efficacy of RNA editing therapeutics are underway, with a focus on optimizing delivery systems, specificity, and long-term outcomes. Additionally, RNA editing biomarkers are being integrated into clinical trial endpoints for patient stratification and therapy monitoring.

Guideline Recommendations

Guidelines from major neurological and genetic societies emphasize the importance of molecular diagnostics and personalized medicine in neurodegeneration. While RNA editing-based therapies are not yet standard of care, expert consensus highlights the need for robust clinical trials, long-term safety monitoring, and ethical oversight. Recommendations encourage the integration of RNA editing research into multidisciplinary care pathways and advocate for patient access to innovative therapies as evidence matures.

Conclusion

RNA editing represents a transformative frontier in the understanding and management of neurodegenerative diseases. By elucidating the mechanistic role of RNA editing and advancing therapeutic technologies, clinicians and researchers are poised to develop precision interventions that address the root causes of neurodegeneration. Continued collaboration between basic scientists, clinicians, and regulatory bodies will be essential to translate these advances into tangible benefits for patients worldwide.